



Signaling Functions of Intramembrane Aspartyl-Proteases

Alkmini A. Papadopoulou¹ and Regina Fluhrer^{1,2*}

¹ Biochemistry and Molecular Biology, Institute of Theoretical Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany, ² German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

OPEN ACCESS

Edited by:

Michael Graham Tomlinson,
University of Birmingham,
United Kingdom

Reviewed by:

Jürgen Bernhagen,
Ludwig Maximilian University of
Munich, Germany
Nhat Tu Le,

Houston Methodist Research Institute,
United States

*Correspondence:

Regina Fluhrer
regina.fluhrer@med.uni-augsburg.de

Specialty section:

This article was submitted to
Atherosclerosis and Vascular
Medicine,
a section of the journal
Frontiers in Cardiovascular Medicine

Received: 05 August 2020

Accepted: 16 November 2020

Published: 14 December 2020

Citation:

Papadopoulou AA and Fluhrer R
(2020) Signaling Functions of
Intramembrane Aspartyl-Proteases.
Front. Cardiovasc. Med. 7:591787.
doi: 10.3389/fcvm.2020.591787

Intramembrane proteolysis is more than a mechanism to “clean” the membranes from proteins no longer needed. By non-reversibly modifying transmembrane proteins, intramembrane cleaving proteases hold key roles in multiple signaling pathways and often distinguish physiological from pathological conditions. Signal peptide peptidase (SPP) and signal peptide peptidase-like proteases (SPPLs) recently have been associated with multiple functions in the field of signal transduction. SPP/SPPLs together with presenilins (PSs) are the only two families of intramembrane cleaving aspartyl proteases known in mammals. PS1 or PS2 comprise the catalytic center of the γ -secretase complex, which is well-studied in the context of Alzheimer’s disease. The mammalian SPP/SPPL family of intramembrane cleaving proteases consists of five members: SPP and its homologous proteins SPPL2a, SPPL2b, SPPL2c, and SPPL3. Although these proteases were discovered due to their homology to PSs, it became evident in the past two decades that no physiological functions are shared between these two families. Based on studies in cell culture models various substrates of SPP/SPPL proteases have been identified in the past years and recently-developed mouse lines lacking individual members of this protease family, will help to further clarify the physiological functions of these proteases. In this review we concentrate on signaling roles of mammalian intramembrane cleaving aspartyl proteases. In particular, we will highlight the signaling roles of PS via its substrates NOTCH, VEGF, and others, mainly focusing on its involvement in vasculature. Delineating also signaling pathways that are affected and/or controlled by SPP/SPPL proteases. From SPP’s participation in tumor progression and survival, to SPPL3’s regulation of protein glycosylation and SPPL2c’s control over cellular calcium stores, various crossovers between proteolytic activity of intramembrane proteases and cell signaling will be described.

Keywords: intramembrane proteolysis, signal peptide peptidase, signal peptide peptidase-like, presenilin, cellular signaling, GxGD aspartyl proteases

INTRODUCTION

Proteolysis is a non-reversible post-translational protein modification and can regulate the function of a protein by contributing to either its maturation and activation, or its degradation. Consequently, the enzymes responsible for proteolysis, the proteases, play a crucial role in regulating key cellular processes, including molecular signaling both within the cell and from cell-to-cell.

Intramembrane proteolysis describes proteolytic processing within the transmembrane domain of membrane-spanning proteins (1). Despite that the process of proteolysis was discovered already in the nineteenth century (2, 3), it had been considered possible only within a fully aquatic environment for the great majority of the past. Only within the past 20 years intramembrane proteolysis became a well-accepted concept and since then the number of proteins undergoing intramembrane proteolysis has increased exponentially (1, 4–7).

Intramembrane cleaving proteases (I-CLiPs) are all multipass transmembrane proteins that cleave their substrates within or very close to the membrane bilayer by most-likely creating a cavity, where water can approach the peptide bond allowing hydrolysis (8–11). I-CLiPs are categorized based on their catalytic centers. The four classes of I-CLiPs are: aspartyl proteases, metalloproteases, serine proteases and glutamyl proteases (12, 13).

This review focuses on mammalian intramembrane aspartyl proteases that, according to a conserved active site motive, are termed GxGD aspartyl proteases (14). This protease class comprises two families, the presenilins (PSs) and the signal peptide peptidases (SPPs). The first family has two members, PS1 and PS2, while the second family has five members: signal peptide peptidase (SPP) and its homologous enzymes, the SPP-like (SPPL) proteases SPPL2a, SPPL2b, SPPL2c, and SPPL3 (15–17). Since the cleavage mechanism and substrate selection of these proteases have been covered in great detail lately (6, 18, 19), this article will concentrate on recent findings that provide insight in how GxGD proteases affect intra- and intercellular signaling. To this end, we specifically summarize cleavage and function of specific validated substrates by aspartyl intramembrane proteases.

SHEDDING AND INTRAMEMBRANE PROTEOLYSIS

A large number of human single-pass transmembrane proteins undergo proteolytic removal of their extracellular domain (ECD), a process termed ectodomain shedding, before they become substrates of intramembrane proteases. This ectodomain shedding is performed by membrane bound and soluble proteases of the extracellular matrix, termed canonical sheddases. If the cleaved ECD is secreted from the cell as a soluble fragment, these proteases are frequently also called secretases. Some of the most well-studied canonical sheddases that cleave their substrates within the luminal juxtamembrane domain include the β -site APP cleaving enzyme 1 and 2 (BACE 1 and 2) and a disintegrin and metalloproteinase (ADAM) family (20). Following the release of the soluble ectodomain, shedded substrates comprise a C- or N-terminal membrane-spanning fragment (CTF or NTF) that is significantly shortened and can only then undergo intramembrane proteolysis (**Figure 1**). This two-step proteolytic cascade is termed regulated intramembrane proteolysis (RIP) and was first described in 2000 (21).

PS1 and SPPL2b have a strong preference of cleaving substrates with short ectodomains that do not exceed 60

amino acids in length. In particular, some of the known PS1 substrates, and also tail anchored proteins, which are substrate to SPP and SPPL2c mediated intramembrane cleavage (22–25), have a naturally short extracellular domain, and, thus, can be cleaved directly by the I-CLiP (19). Additionally, some I-CLiPs are known to directly accept substrates with long and bulky ECDs. Most of these proteases belong to the family of serine intramembrane proteases called rhomboids (26), but also SPPL3 is performing direct cleavage of substrates with long ectodomains (**Figure 1**) (18, 27–29). These I-CLiPs are referred to as “non-canonical” sheddases (20).


In addition, multipass TM proteins can also undergo RIP. For a single pass transmembrane protein, the cleavage within or at the border of the transmembrane domain leads to the release of an extracellular fragment at the luminal or extracellular side, and an intracellular domain (ICD). While, for multipass transmembrane proteins, the first cut leads to the breakage of a loop and the second cut takes place within the transmembrane domain (27).

GxGD ASPARTYL-PROTEASES

PS1 and 2 were the first GxGD aspartyl-proteases discovered. Their discovery followed the research into the pathogenesis of Alzheimer's disease, the most prevalent form of dementia (30–34).

The second family of GxGD aspartyl-proteases, the SPP/SPPLs, were discovered by database sequence homology analysis based on the PS sequence, as well as by biochemical methods (15–17). All seven human GxGD aspartyl proteases have a multi-transmembrane domain protein structure consisting of nine transmembrane domains (18). The two aspartic acids that comprise their active site, are located within conserved transmembrane domain motifs. The first aspartic acid is located in a YD motif in transmembrane domain 6. The second aspartic acid is part of the GxGD motif, found in transmembrane domain 7, which also gives the name to this class of proteases. These aspartic acids are essential for the catalytic activity of the proteases, as mutating either of the aspartic residues almost completely abolishes catalytic activity of the protease (17, 28, 35–39).

Another characteristic that is shared by all GxGD aspartyl proteases, is a conserved PAL motif in transmembrane domain 9. Mutations in the PAL motif have been shown to negatively affect the proteolytic ability of at least SPP and PS, however its purpose has so far only been investigated in the γ -secretase complex (18, 40–42). The involvement of the PAL motif in the architecture of the active site and substrate recognition had been speculated for many years (43). Recent analysis of the 3D structure of γ -secretase cross-linked with its substrate APP confirmed that the PAL motif is involved in substrate recognition and even showed that the PAL motif is directly binding a β -strand of the substrate (44). It is, thus, tempting to speculate that the PAL motif functions as a gate keeper for the substrate to enter the active site and although it has not been investigated so far, it could serve a similar purpose in SPPLs.



A key difference between the PS and the SPP/SPPL family, is their reversed membrane topology. The N-termini of PSs are located in the cytosol, while SPP/SPPLs have their N-termini in the lumen or extracellular space (45, 46). As this leads to inverted topology of their active sites, it might account for their specificity of cleaving substrates with opposite membrane orientation. PSs only cleave type-I transmembrane proteins, with their N-termini in the lumen or extracellular space, while SPP/SPPLs only cleave type-II transmembrane proteins, with their N-termini in the cytosol (6, 18).

Although some of the SPP/SPPLs are thought to undergo multimerization and have been observed as homodimers or tetramers, they most likely do not require additional cofactors for their catalytic activity (46–48). On the other hand, PSs are only active as part of the γ -secretase complex and favor endoproteolysis in their cytosolic loop between transmembrane domain 6 and 7, forming PS CTF and NTF to be active (19, 49).


The γ -secretase complex is formed by PS1 or 2 together with three additional proteins, presenilin enhancer 2 (PEN-2), anterior pharynx defective-1 (APH-1), and nicastrin (NCT) (Figure 2). PEN-2 is a two-transmembrane domain protein that is necessary both for endoproteolysis of PSs and for stabilization of PS CTF and NTF (50–52). APH-1 comprises seven transmembrane domains and a GxxxG motif is believed to act as a connecting subunit holding together NCT with PS NTF and CTF (53). The last member of the complex, NCT, is a single pass transmembrane protein with a large and heavily glycosylated ectodomain. Due to the size, position and charge of the NCT's ectodomain, it is proposed to act as the “gate keeper” in the

complex, recognizing the substrates and allowing only proteins with a short ectodomain to enter the active site (54, 55).

Another interesting characteristic of the γ -secretase complex is its unusually slow proteolysis speed. This characteristic was initially observed on the processing of the β -amyloid precursor protein (APP) (56) and was later confirmed on the processing of the epithelial cell adhesion molecule (EpCAM)-CTF (57). It is not clear if the low speed is due to substrate recognition, binding or the proteolysis itself, however similar results had been obtained previously for rhomboid proteases (58). It has not yet been investigated whether this applies to the other members of the GxGD class of proteases but it does not appear as if these proteases have been purposed for a fast turnover rate.

PS 1 and 2 homologs are roughly 65% identical and both can be part of γ -secretase complexes, cleaving the same substrates *in vitro* (59). Familial mutations causing Alzheimer's disease have mainly been detected in *PSEN1*, the coding gene for PS1 and to a lesser degree in *PSEN2* (30–34). The γ -secretase complex containing PS1 has been reported to have a higher affinity for APP, and also to localize to different subcellular compartments than PS2 containing complexes. PS1 complexes can be detected on the plasma membrane (Figure 2), while PS2 complexes are targeted to late endosomes and lysosomes (60, 61).

The key product of γ -secretase cleavage that led to its discovery is the amyloid β -peptide (A β). Aggregation of A β molecules in the central nervous system is a hallmark of Alzheimer's disease (14, 62–64). Production of A β is a well-studied process that results from the amyloidogenic processing of the type-I membrane protein APP, however it is not the only possible product of the γ -secretase processing (27). During RIP, APP is initially shedded by either ADAM10 or BACE1



(20). Each sheddase prefers a distinct cleavage site and cleavage by ADAM10 (α -secretase) (65) releases a longer soluble APP (sAPP α) and a shortened CTF α . This is considered the non-amyloidogenic processing as cleavage of CTF α by γ -secretase releases APP ICD (AICD) and the p3 peptide, which is smaller, less hydrophobic and less prone to aggregation than A β (66). On the contrary, shedding of APP by BACE1 (β -secretase) releases a shorter sAPP β and a longer CTF β . Processing of CTF β by γ -secretase results in release of the same AICD and the A β peptide, which is longer than p3 and prone to aggregation making this the amyloidogenic processing (10, 67–69). Although AICD has been suggested to possess transcriptional functions as seen in other ICDs (70, 71), its fast degradation stands against those hypotheses.

The SPP/SPPL family members are characterized by more heterogeneity and less substrate overlapping than the PSs. SPP, the first discovered protease of this family, is retained to the

endoplasmic reticulum (ER) by a C-terminal KKXX-sequence (17). From the three SPPL2 proteins, SPPL2a and SPPL2b share more similarities and some substrate overlap, especially *in vitro*. SPPL2a is mostly transported to the lysosomes/late endosomes via its C-terminal YXX ϕ sorting signal, while SPPL2b most likely localizes to the plasma membrane (**Figure 2**) (38, 72). Additionally, their expression patterns within the organism differ with SPPL2a being expressed more ubiquitously and SPPL2b mainly in the central nervous system, bone marrow and lymphoid system (73).

SPPL2c has a different localization in the cell, as well as in the whole organism and also differs in its substrate spectrum from the other two SPPL2 proteases. For a long time, it was considered to be a pseudogene and a pseudoprotease, as no SPPL2c protein levels were detected *in vivo* and no substrates had been identified. This concept changed last year when two papers demonstrated SPPL2c protein expression and identified physiological substrates

of this protease. Expression of the protein *in vivo* was found only in a specific cell type within the testis, while its cellular localization is in the ER/ER-Golgi intermediate compartment (ERGIC) (**Figure 2**) (24, 25).

Last but not least, SPPL3 is the smallest member of this family, it is localized in the Golgi and it is not glycosylated (**Figure 2**). In contrast to all other GxGD aspartyl proteases, SPPL3 acts exclusively as non-canonical sheddase and directly cleaves full-length substrates with very long ectodomains, resulting in the release of soluble ectodomains to the Golgi lumen and, consequently, also to the extracellular space (28, 29, 74).

INTRAMEMBRANE PROTEOLYSIS AND SIGNALING

Intramembrane proteolysis is capable of directly controlling the abundance of certain membrane proteins, and thus, also their local activity. In this scenario, reduced proteolytic cleavage would result in increased presence of the substrate on the membrane and vice versa. The accumulating substrate of intramembrane proteolysis could be either the full length protein, in the case of non-canonical shedding, or the membrane bound remaining product of shedding, in the case of RIP. If this substrate's role positively impacts on signaling while spanning the membrane, then reduction of the protease activity, would result in increased signaling. Such is the case, for example, with signaling induced by the accumulation of Lectin-like oxidized LDL receptor 1 (LOX1) NTF when the activity of SPPL2a or SPPL2b is reduced (75). On the contrary, if this substrate has an inhibitory function by its presence on the membrane, as for example does FKBP8, a substrate of SPP, increased proteolysis would decrease its inhibitory function and boost signaling (76).

However, not all substrates fulfill their functions while attached to the membrane. In certain cases, cleavage of the substrate plays an integral part in the signaling cascade and is needed for a signal to be passed forward via the cleavage products. In these cases the various products of cleavage can function as distinct signaling molecules. In such scenarios reducing proteolytic cleavage would actually inhibit the signal transmission. For instance, when a transmembrane substrate undergoes cleavage in the secretory pathway or at the cell surface, a part of it can be released to the compartment lumen or extracellular space. In particular protein domains released to the extracellular space may serve a purpose by binding to a receptor on a neighboring or even far distant cell in the body. This scenario is most common for canonical sheddases, such as the shedding of tumor necrosis factor- α (TNF α) by ADAM17 (77, 78), but is also a function of non-canonical sheddases, as seen for shedding of epidermal growth factor (EGF) by rhomboid-related protein 2 (RHBDL2). Although SPPL3 is also a non-canonical sheddase, no purpose has so far been identified for the secreted extracellular domains of its substrates (28, 29).

At the same time, intramembrane cleavage also triggers the release of the substrate's intracellular domain. Although these intracellular peptides are often unstable and undergo rapid degradation, in certain cases they are known to translocate to the

nucleus where they can either directly or in collaboration with other transcription factors activate or deactivate the transcription of target genes. A well-known example in this category is the release of the Notch ICD by γ -secretase, which translocates to the nucleus and induces the expression of specific genes (79).

Intramembrane proteases can have also an indirect effect on signaling. Although there are numerous such possibilities, some key indirect effects of I-CLiPs on signaling include changes in localization, trafficking and glycosylation of signaling molecules, as well as influences on calcium signaling. I-CLiPs are capable of affecting the abundance of key trafficking molecules by, for example, cleaving key trafficking factors, such as the soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor proteins (SNAREs), which are substrates of both SPP and SPPL2c (25, 80). In that case, increased I-CLiP activity would result in decreased trafficking of various cargo molecules and, thus, certain signaling molecules cannot reach their target localization either within or outside the cell. Glycosylation of secretory proteins can be affected by, for example, proteolytically inactivating glycosylating enzymes in the cell, as is the case with SPPL3 dependent cleavage of glycosidases and glycosyltransferases (28, 29). Thus, changes of the protease activity can directly impact on the glycosylation pattern of a cell.

Beside the knowledge of the general impact of intramembrane cleavage on signaling, some specific cellular processes that are influenced by GxGD aspartyl proteases have been in focus of research in the past years.

INTRAMEMBRANE PROTEOLYSIS IN SIGNALING OF THE VASCULAR SYSTEM

Very recently involvement of SPPL2a/b in the signaling of the vascular system was discovered (75). In this study, the authors demonstrate that LOX1 is initially cleaved by either ADAM10 or lysosomal proteases, and the remaining membrane associated LOX1 NTFs are cleaved by SPPL2a/b. Cleavage of LOX1 NTFs by SPPL2a/b takes place either on the cell surface or in the lysosomes and, consequently, leads to the reduction of LOX1 NTF levels and the release of LOX1 ICD into the cytosol. Although the LOX1 ICD function remains enigmatic, accumulation of LOX1 NTF induces proatherogenic and profibrotic signaling and therefore their removal is atheroprotective. For more details regarding the participation of SPPL2a/b in the signaling process of LOX1 and their atheroprotective function, please refer to a detailed review by Mentrup et al. included in this issue.

The invariant chain (CD74) of the major histocompatibility class II complex (MHCII), another substrate of SPPL2a, appears to be connected to the formation of atherosclerosis, CD74 has been validated to undergo RIP *in vivo* being initially shedded by serine or cysteine proteases, releasing the CD74 soluble ectodomain (CD74 ECD). SPPL2a then cleaves the remaining NTF intramembranously releasing the CD74 ICD (6, 81). The main purpose of CD74 is related to the function of the immune system, however levels of CD74 were found to be increased in human atherosclerotic plaques contributing to the pathology (82). Another study using

low-density lipoprotein receptor-deficient mice ($Ldlr^{-/-}$) as a model of familial hypocholesterolaemia, showed that additional deficiency of CD74 ($Ldlr^{-/-}$ $Cd74^{-/-}$) had a protective effect on atherosclerosis (83). Although it was shown that this effect most likely was connected to the impairment of the adaptive immune system, it has so far not been investigated which part of the CD74 protein is responsible for this effect. It remains to be seen whether lack of the full length CD74 is necessary, or targeting the release of one of the products of RIP (CD74 ECD, NTF, or ICD) would be sufficient for the protective role. The soluble CD74 ECD has already been connected to signaling functions in context of the macrophage migration inhibitory factor (MIF) related to cardiovascular diseases (84). The function of the CD74 intramembrane cleavage products, however, so far, remains enigmatic.

The formation of the vascular system is crucial both during development and regeneration, while it can be detrimental under pathological conditions, such as cancer (85, 86). New blood vessels are created via endothelial cell sprouting and proliferation, a process that needs to be tightly regulated via cell-to-cell communication (87, 88). Endothelial cells are activated by angiogenic signals, primarily through vascular endothelial growth factor A (VEGF-A), becoming the tip cells of angiogenesis. This initiates the expression of a series of proteins including VEGF receptors 2 (VEGFR2) and delta-like-4 (Dll4) (Figure 3). Some of these proteins act as signaling molecules on neighboring endothelial cells suppressing their activation and turning them to stalk cells, defining the new vessel. The main mechanism by which this is achieved is the activation of the NOTCH receptors on stalk cells by their ligands, such as Dll, which in turn can have an effect on the expression of VEGFR on neighboring tip cells (89).

PSs, as part of the γ -secretase complex, are connected to the vascular system and angiogenesis through a number of their substrates that include the receptors Notch, VEGFR-1 and others (5). In addition, non-proteolytic functions of presenilin related to its phosphorylation or the translocation of these receptors have also been discussed in the context of vasculature and angiogenesis but will not be covered further here (90–92).

The Notch signaling pathway is highly conserved in evolution and it has been studied in great depths. It has a clear connection to both the physiological formation of the vascular system, promoting the formation of arteries (93), but also to pathological angiogenesis, as seen in breast cancer and other types of cancer (94–96). The importance of the NOTCH pathway in the health of the vascular system can be confirmed as defects in this pathway can cause Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) (91).

After activation of one of the four Notch receptors by a neighboring cell presenting one of Notch's transmembrane ligands, Dll 1, 3 or 4, Notch is cleaved first by ADAM10 and then by γ -secretase, releasing the Notch ICD (NICD) into the cytosol. NICD can translocate to the nucleus and bind the transcription factor CSL acting then as a transcriptional activation complex leading to the expression of downstream HES and HEY family genes (Figure 3) (79). It has been shown that Dll4 is the principle Notch ligand expressed by vascular epithelial cells and

its haploinsufficiency is enough to cause a lethal phenotype in mice (97–99). Interestingly, inhibition of Notch CTF cleavage by a γ -secretase inhibitor is enough to reproduce an effect in Notch signaling similar to Dll4 haploinsufficiency (100). These results clearly demonstrate that γ -secretase cleavage is performed following the activation and shedding of the Notch receptor and is indispensable for the Notch ICD dependent signaling. In line with this, deletion of PS1 in mice ($PS1^{-/-}$ mice) is sufficient to reproduce the embryonically lethal phenotype observed in Notch $^{-/-}$ mice (101–103). While $PS2^{-/-}$ mice are viable with a minor motor phenotype (104), $PS1^{-/-}$ suffer embryonic death with severe axial skeleton (102) and central nervous systems defects (101), as observed in Notch $^{-/-}$ mice (105, 106).


Interestingly, Notch ligands, including Dll and Jagged (Jag), have also been suggested to undergo RIP, with ADAM17 performing the first cut and γ -secretase releasing their ICDs (107). Although it is very stimulating that Notch and its ligands can undergo cleavage by the same machinery, the purpose of this mechanistic overlap or the fate of the released ligand ICDs remains unclear.

VEGFR1 is highly similar to VEGFR2 and has a very high affinity for VEGF, however its kinase activity is significantly reduced and plays a more variable role as it can regulate the VEGFR2 induced angiogenesis (108, 109). Pigment epithelium-derived factor (PEDF) is the most potent endogenous negative regulator of blood vessel growth and its ability to block the formation of new vessels seems dependent to VEGFR1 expression (90). Interestingly, it has been reported that VEGFR1 is not only cleaved by γ -secretase as part of RIP, but it also appears that this cleavage can be boosted by PEDF (90). Increased activity of γ -secretase in response to PEDF treatment could help VEGFR1 fulfill its purpose as negative regulator of VEGFR2-induced angiogenesis by participating in the trafficking and intracellular translocation of VEGFR1 CTF and inhibiting the phosphorylation of VEGFR1 following VEGF binding (92). Although γ -secretase has an effect on VEGFR1 function and leads to the production of a VEGFR1 ICD from the VEGFR1 CTF that is then degraded by the proteasome, the purpose and extent of this regulation, as well as whether γ -secretase has indeed a role in trafficking and phosphorylation is so far not clear under physiological conditions (92).

As PSs are involved in vasculature signaling and pathological angiogenesis is essential in the formation and progression of tumors, it is of great interest to understand how PSs and SPP/SPPLs may affect cancer progression.

INTRAMEMBRANE PROTEOLYSIS IN CANCER-ASSOCIATED SIGNALING

Pathological angiogenesis is needed for tumors to grow, as they require a high supply of nutrients and oxygen. The Notch receptor plays a key role for the formation of new vessels and it has been shown since many years that it is also an important contributor during malignant angiogenesis in both hematopoietic and solid tumors (110). Ligand-induced Notch signaling is often increased and dysregulated




during pathological neoangiogenesis and targeting this signaling pathway can be achieved by targeting either the receptor itself (pan-Notch inhibitors and specific Notch receptor antibodies) or targeting ligands that are specific to the angiogenic functions. As the most common ligands of Notch during angiogenesis that are also found to be upregulated in cancer, Dll4 and Jag1 have both been targeted for treatment of breast cancer tumors, with Dll4 being a more established focus point (111, 112).

It has been shown that ligand-induced signaling via the Notch receptor requires cleavage by γ -secretase for the production of NICD that then translocates to the nucleus and affects transcription (Figure 3) (79). Consequently, γ -secretase inhibitors are being evaluated for their ability to block this signaling pathway showing positive results in preventing tumor promotion and inducing tumor cell death both *in vitro* and *in vivo* (113–117). However, Notch inhibition via γ -secretase mainly works with additional treatments as it can only be tolerated for short times. This is partly due to the numerous substrates cleaved by γ -secretase, leading to many side-effects after prolonged inhibition (118, 119). Another important reason for balancing the intensity and extent of γ -secretase inhibition are the tumor-suppressing roles of Notch, due to its participation in definitive haematopoiesis (120) and

T-cell development (121, 122). It has already been shown in mouse models that γ -secretase inactivation by NCT deletion can cause chronic myelomonocytic leukemia in a Notch-dependent manner (123).

Another family of molecules involved in signaling that are tightly connected to cell proliferation, differentiation, apoptosis and, thus, also cancer are the receptor tyrosine kinases (RTKs) (124). Half or more of the known RTKs to date are also substrates of γ -secretase following initial shedding by ADAM10 or 17 (Figure 4A). γ -secretase releases RTK ICDs, which include the tyrosine kinase domain and can translocate to the nucleus or are subject to proteasomal degradation. In the nucleus, the RTK ICDs can interact with transcriptional regulators to affect cell proliferation, survival and differentiation, while translocation to the proteasome results in rapid degradation (Figure 4A). ErbB-4 was the first RTK discovered to be cleaved by γ -secretase via RIP generating the ErbB4 ICD (E4ICD) (125). Nuclear translocation of the E4ICD regulates the transcription of genes related to the pro-apoptotic function of ErbB4, while inhibition of γ -secretase blocks the effect on gene expression (125–127). Many more RTKs have been identified as γ -secretase substrates, including EphA4, EphB2, IGF-1R (128, 129). As altered RTK signaling has been linked to carcinogenesis, with for example increased E4ICD promoting growth of breast cancer cells *in vitro* and *in vivo* in



mice, dysregulation of the RIP process could promote tumor progression (129, 130).

The participation of γ -secretase activity in cancer progression is not limited to the already mentioned substrates. Numerous more proteins that are involved in the pathology of cancer progression have been shown to undergo cleavage by γ -secretase, as part of a more complex mechanism. Some notable substrates include CD44 (131), E-cadherin (132), and epithelial cell adhesion molecule (EpCAM) (133). However, despite the anti-tumor effect of γ -secretase inhibitors, their adverse effects due to cleavage of multiple substrates make their use in patient treatment very complicated (116).

In addition to PS, also SPP has been implicated in development and progression of cancer. For instance, its expression levels are found to negatively correlate with overall survival and recurrence free survival in lung and breast cancer (76). Two different substrates of SPP have been identified that could be responsible for this effect: heme oxygenase-1 (HO-1) and FKBP8. HO-1 is an enzyme attached to the ER membrane via a C-terminal tail anchor and is responsible for heme-degradation. It is stress-inducible, cytoprotective and highly expressed in numerous cancers, promoting the tumour's survival, growth and angiogenesis (134, 135). Part of HO-1's cancer boosting activity is unrelated to its enzymatic activity, but attributed to the nuclear translocation of HO-1 ICD (**Figure 4C**). As HO-1

is cleaved by SPP within its membrane-spanning domain, HO-1 ICD production and nuclear translocation is reduced with SPP knockdown and increased with SPP overexpression. Increased expression of SPP by the tumor cells, would thus increase the cleavage of HO-1, protecting the tumor from cellular stress and boosting its growth (**Figure 4C**) (22, 23).

FKBP8 is a non-canonical member of the FK-506-binding protein (FKBP) family, a tail anchored type-II transmembrane protein located in the ER and an endogenous inhibitor of the mTORC pathway (**Figure 4B**) (136). FKBP8 was identified as an SPP substrate via a proteomic approach (76). Cleavage of FKBP8 by SPP leads to an overactivation of the mTORC pathway, which in turn causes an increase in cell growth, migration and invasion of tumor cells. This effect could be rescued by suppression of the mTORC pathway demonstrating the involvement of SPP in the mTORC signaling pathway (**Figure 4B**) (76).

As levels of SPP have been proven to be upregulated in different forms of cancer and often correlate with poor prognosis for the patient, while inhibition of SPP activity *in vitro* seems to suppress the tumor growth (76, 137), it is of interest to consider inhibition of SPP as a treatment method. Despite ongoing research in the field of SPP/SPPL inhibition, the identification or synthesis of specific inhibitors has been unfruitful so far. 1,3-di-(N carboxybenzoyl-leucyl-L-leucyl) amino acetone [(Z-LL)₂-ketone] is one of the best inhibitors of SPP, which was also

used to isolate and identify the protease (17, 138). Although (Z-LL)₂-ketone spares the activity of γ -secretase, SPPL2c and SPPL3, it inhibits SPPL2a and SPPL2b dependent cleavage (37, 39, 139, 140) making it an unsuitable inhibitor for treatment. A lot of research has been done in an effort to develop specific SPPL2a inhibitors (141, 142) and some of these inhibitors are also targeting SPP while having decreased affinity to other proteases, such as γ -secretase (143). The research on these inhibitors and their structures could be used as a solid basis to develop specific SPP inhibitors in the future. However, even when a specific SPP inhibitor is discovered, its use would have to be carefully considered and restricted due to the numerous important physiological functions of SPP. These functions include cleavage and removal of signal peptides (144), participation in endoplasmic reticulum-associated degradation (ERAD) (145) and others.

INTRAMEMBRANE PROTEOLYSIS IN SIGNALING OF THE IMMUNE SYSTEM


Multiple members of the SPP/SPPL family have been shown to be involved in proper function of the immune system. In most cases, the exact mechanism on how SPP/SPPL proteases affect survival, maturation and function of certain immune cells remains elusive, as is the case with SPPL3's function in natural killer (NK) cells. SPPL3 deficiency results in impairment of NK cell maturation in a cell autonomous manner that is dependent on the catalytic function of SPPL3 (146). In NK-cell specific conditional knockout mice, not only the number of peripheral NK cells was reduced, but also the remaining cells had reduced cytotoxicity and expression of numerous NK cell surface receptors (19, 146). Although, it has been shown that the proteolytic activity of SPPL3 is necessary for the correct maturation of NK cells suggesting the existence of one or more specific substrates involved in this process, these substrates have not been identified so far (146). As NK cells play an important role in natural cancer immunosurveillance, SPPL3 malfunction could be connected to decreased NK cell numbers and thus decreased immunosurveillance (147).

In addition, SPP has also been demonstrated to affect the function of NK cells, but in this case an indirect mechanism was identified. SPP affects the presentation of histocompatibility antigens on the cell surface of healthy cells. Lack of such antigens makes cells a target for NK cells, as they are considered unhealthy. SPP generates these peptides that then bind to HLA-E receptors and are presented on the cell surface, in different ways. Either by cleaving the signal peptide of polymorphic major histocompatibility (MHC) class-I molecules in the ER in collaboration with signal peptidase (148), or from non-MHC-signal peptides (149), or independently of signal peptidase, directly from multipass TM proteins (150). SPP, thus, contributes to multiple mechanisms for providing signals for the circulating NK cells. As NK cells rely on these signals to recognize the organism's cell as healthy, lack of such peptides on the cell surface would cause the circulating NK cells to attack and kill these cells (151, 152).

Thus, lack of SPP activity could cause the immune system to attack cells that are otherwise healthy due to lack of "self-recognition" peptides.

SPPL2a has been found to play a crucial role within the immune system. Compromise of the SPPL2a proteolytic activity causes a defect in the maturation of splenic B cells and conventional dendritic cells (cDCs) (139, 153–155). The substrate of SPPL2a responsible for this phenotype is CD74, the first verified SPPL2a substrate *in vivo* (139, 153, 154). CD74 is a type-II TM protein expressed in antigen presenting cells. It acts as a chaperone for the MHC class II complexes, assuring that no premature peptides bind to the complex. In order for antigen-derived peptides to bind to MHC class II, CD74 is degraded. To this end, it undergoes RIP being cleaved first by serine or cysteine proteases, such as cathepsin S, producing the membrane bound CD74 NTF. This NTF is then cleaved in the transmembrane domain by SPPL2a (**Figure 5A**) (6, 81). Although the CD74 ICD generated from this proteolytic cleavage can translocate to the nucleus and potentially affect the NF- κ B signaling pathway (**Figure 5A**) (156), lack of CD74 ICD is not responsible for the observed phenotype. Instead, the phenotype is caused by the accumulation of CD74 NTF upon SPPL2a deficiency, which in turn causes structural changes in endocytic compartments and disturbances of trafficking (**Figure 5B**) (139, 154). As a result of this, presence of the key B cell maturation receptors BAFF and B cell antigen receptor (BCR) on the cell surface is reduced (**Figure 5B**). Reduced signaling from these receptors would account for the reduced differentiation and maturation (139, 154). Removing expression of both SPPL2a and CD74, rescues the structural changes in the subcellular compartments and the maturation of B cells in mice. This phenotype is also partly conserved in humans as mutations that reduce SPPL2a expression cause an accumulation of CD74 NTF in B cells. Although no maturation defect was observed in humans, the partial loss of cDCs seen in mice was observed in human samples and is thus conserved in both species (155, 157).

Additional known SPPL2a and/or SPPL2b substrates are also involved in proper function of the immune system, such as TNF α and Fas ligand (FasL), however cleavage of these substrates has only been validated in cell culture model systems so far (37–39). Fas ligand (FasL) is a type-II transmembrane protein with very restricted expression that belongs to the superfamily of TNF cytokines. Its binding to the Fas receptor induces apoptotic cell death, and mutations on either the ligand or the receptor can cause autoimmune lymphoproliferative syndrome (ALPS) (158). FasL can undergo RIP, being cleaved initially by ADAM10 and then SPPL2a, which releases the FasL ICD. This ICD can translocate to the nucleus where it performs reverse signaling, reducing the activation-induced proliferation in B and T cells (39, 159). Even though the physiological relevance of the release of the FasL ICD by SPPL2a remains unclear, the reverse signaling performed by the ICD could be important in preventing hyperactivation of the immune system and/or terminating an immune response following antigen stimulation (159). In this case decreased SPPL2a proteolytic activity would prolong immune responses possibly also leading to autoimmunity or allergies, while increased cleavage by SPPL2a could stop the



immune response before the threat is under control, showing the importance of fine-tuning such processes.

TNF α is a type II transmembrane protein that undergoes RIP being cleaved first by ADAM17, releasing soluble TNF α , and then by SPPL2a/b releasing TNF α ICD (37, 38). Soluble TNF α is a proinflammatory cytokine, the release of which can be induced in macrophage cell systems by stimulating the cells with lipopolysaccharide (LPS). It has been reported that TNF α ICD, released by SPPL2a/b, can stimulate the expression of Interleukin 12 (IL-12), another proinflammatory cytokine. IL-12, is released by LPS-stimulated dendritic cells, but inhibition or downregulation of SPPL2a and/or SPPL2b, led to an inhibition of IL-12 production by stimulated mature dendritic cells (mDCs). Additional treatment with TNF α ICD rescued IL-12 expression upon stimulation (38). However, it remains unclear whether such a mechanism can be seen *in vivo*.


IMPACT OF INTRAMEMBRANE PROTEOLYSIS ON SUBCELLULAR TRAFFICKING

Trafficking clearly holds a key role in signaling, as the signaling molecules and receptors need to be present in the correct time

and place, both for a signal to be sent but also to be received and processed. SPP/SPPLs do not only affect trafficking indirectly, like in case of CD74, but also directly by cleaving proteins that are central mediators of trafficking. This has been shown for SPP and for SPPL2c, both of which localize to the ER but with SPPL2c being expressed only in a very specific cell type in testis. SPP and SPPL2c are capable of cleaving SNAREs, which are required for targeted and successful fusion of membrane vesicles at their destination and in their majority are tail-anchored type-II (type IV) transmembrane proteins (**Figure 6A**) (24, 25, 80).

As cleavage of SNARE proteins would cause an inhibitory effect on vesicular trafficking, the wide expression of SPP across species and cell types predisposes for a limited number of substrates in the SNARE family (18). Indeed, so far only one member of the SNARE family, syntaxin 18 (Stx18), has been validated as an SPP substrate (**Figure 6B**). Nevertheless, given the crucial role of Stx18 in the organization of the ER membranes, ectopic expression of SPP led to a reorganization of ER morphology that could be rescued by co-expression of Stx18 (80). However, the physiological relevance of this phenotype under endogenous conditions remains unclear (19).

Contrary to SPP, SPPL2c expression is extremely restricted. After remaining elusive for many years, expression was finally




reported just last year, in testis of male mice and humans, specifically in elongated spermatids, where it resides either in the ER or pre-Golgi compartments (24). The high levels of SPPL2c expression found in this limited number of cells that undergo significant reorganization to form mature sperm, induces compartment reorganization by impairing vesicular trafficking. Ectopically expressed SPPL2c in HEK 293 cells has been shown to cleave numerous SNARE proteins, including Stx5, Stx8, Stx18, VAPA, VAPB, and others, while Stx8 was also identified as an SPPL2c substrate *in vivo* in mouse testis (25). Cleavage of SNARE proteins in HEK293 leads to reduced vesicle transport from the ER, reduced maturation and glycosylation of various secretory and membrane proteins (**Figure 6B**). Prolonged expression of SPPL2c causes structural alterations on the compartments of the secretory pathway, in particular the ER and the Golgi (25). The pronounced effects of SPPL2c expression on the secretory pathway most likely explain its very restrictive endogenous expression. SPPL2c deficiency in mice leads to reduced mobility of sperm, altered glycosylation pattern of the glycocalyx and apparent defects in the formation of the acrosome (24, 25). As SPPL2c expression was observed in the very same cell type in human samples (24), it is very plausible that it could be involved in male infertility and would be worth investigating. Furthermore, based on the results from mating SPPL2c deficient mice, it appears that SPPL2c would also play a role in the fertility of female mice (24). So far, the limited amount of mature oocytes produced in every cycle and their short life span has not allowed for further research into this aspect, it does remain, however, of

high interest as it might be connected to infertility problems in humans.

IMPACT OF INTRAMEMBRANE PROTEOLYSIS ON CALCIUM SIGNALING

Calcium (Ca^{2+}) acts as a very important second messenger, which is induced by various intracellular signaling cascades. Changes in the intracellular Ca^{2+} concentrations are involved in a variety of cellular processes in both physiological and pathological conditions (160). PS, SPPL3 and SPPL2c have all been associated to calcium-dependent signaling (24, 161). For SPPL3 this effect has been linked to the modulation of NFAT transcription factor activity, but was shown to be independent of its proteolytic function. This is the only non-proteolytic function attributed not only to SPPL3, but to any of the members of the SPP/SPPL family. SPPL3 presence reportedly enhances the interaction between stromal interaction molecule 1 (STIM1) and Orai, thus enhancing the store-operated Ca^{2+} entry (SOCE) leading to Ca^{2+} influx. The interaction of these two proteins and subsequent Ca^{2+} influx play a key role in the transmission of signaling from the T-cell receptor (TCR) to the NFAT transcription factors (161). This effect though it boosts the response to TCR signaling, has so far only been confirmed in cell culture models and its physiological relevance remains unclear.

PSs, as part of the γ -secretase complex, have also been implicated in the regulation of intracellular Ca^{2+} levels and Ca^{2+} signaling (162–164). Although this mechanism appears



independent of the proteolytic function of γ -secretase, it is affected by PS mutations that are linked to familial Alzheimer's disease (FAD) (165, 166). PSs are suggested to be involved in this phenotype by a multitude of mechanisms. PSs can form ER Ca^{2+} leaking channels, the function of which is disturbed by the FAD mutations (162). They can also interact with the sarco ER Ca^{2+} -ATPase (SERCA) pumps (163) and lastly, release Ca^{2+} from stores through the inositol trisphosphate receptor (InsP_3R) by agonistic activation (164). The participation of PS in physiological Ca^{2+} signaling and the disturbance of the balance by the presence of FAD mutations is considered as a possible contributor to Alzheimer's disease pathology but remains under debate in the field.

In case of SPPL2c, the effect on calcium-signaling is dependent on cleavage of its *in vivo* validated substrate phospholamban (PLN) (24). PLN is a small tail anchored protein that resides in the ER and can regulate the transport of Ca^{2+} in and out of the ER (Figure 7). In wildtype elongated spermatids, the physiological expression of SPPL2c results in cleavage of PLN and a particular Ca^{2+} balance in those cells (Figure 7A) (24). In mice that lack SPPL2c, PLN levels were increased and cytosolic Ca^{2+} levels were found to be decreased (Figure 7B). This finding might be related to the movement capabilities of mature spermatids (24).


IMPACT OF INTRAMEMBRANE PROTEOLYSIS ON PROTEIN GLYCOSYLATION

Glycans are attached to a large number of cellular proteins, mainly transmembrane and secreted proteins, in a variety of combinations and positions. In many cases this can affect the function and localization of these proteins, including functions like cell-cell recognition and communication (167). The precise pattern of glycosylation needs to be tightly regulated as altered

glycosylation patterns have been linked to numerous pathologies (168), including cancer (169, 170) and Alzheimer's disease (171). SPPL3 and SPPL2c have both been shown to affect protein glycosylation, in a direct and indirect manner, respectively (25, 28).

SPPL3 directly cleaves numerous type-II TM glycosidases and glycosyltransferases in the Golgi (Figure 8). Cleavage takes place within or in close proximity to the TM domain of the protein and leads to the release of a soluble domain, which can be found in the supernatant of cell culture models, but also in human body fluids like blood (Figure 8A) (172–175). Of note, the secreted ectodomain of the glycan modifying enzymes contains the active site responsible for protein-glycosylation. Although these soluble glycosylating enzymes remain in principle active, the lack of nucleotide activated sugar donors in the extracellular compartment renders them most likely inactive (168, 176, 177). Thus, by controlling the amount of numerous active glycosylating enzymes in the Golgi, SPPL3 can affect the global glycosylation pattern of a cell and consists an easy switch to alter this pattern by affecting a single protein. It has been shown in cell culture and *in vivo* that lack of SPPL3 activity leads to an accumulation and/or decreased secretion of glycan modifying enzymes and, consequently, to hyperglycosylation of a variety of cellular glycoproteins (Figure 8B). While increased activity of SPPL3 has the opposite effect and results both in increased secretion of the soluble glycosidases and hyperglycosylation of glycoproteins (Figure 8C) (28, 29).

The most well-characterized substrate of SPPL3 is N-acetylglucosaminyltransferase V (GnTV), a Golgi localized enzyme that belongs to the family of N-acetylglucosaminyltransferases (GnTs) that are responsible for N-acetylglucosamine (GlcNAc) branching during the formation of complex N-glycans (Figure 8) (28, 178). Interestingly, levels of GnTV have also been found to increase in early stages of many cancers (179, 180). Often the increase of GnTV negatively



correlates with patient survival, this is however seen only in specific types of cancer, such as renal cancer (181). Increased presence and activity of GnTV leads to hyperglycosylation of specific cell surface receptors. This increases their presence on the plasma membrane and is connected to cancer growth and metastasis through enhanced growth factor signaling (179). Recent studies are trying to target GnTV in an effort to treat cancer (182). Presence of SPPL3 can strongly affect levels of endogenous GnTV with MEF cells from SPPL3 knockout mice clearly accumulating mature GnTV (28). Reduction of SPPL3 activity would thus, not only interfere with NK cell maturation, but also negatively affect the cellular glycosylation pattern setting up a favorable environment for tumorigenicity. SPPL3 could indeed be involved in tumorigenicity as some single nucleotide polymorphisms (SNPs) in the coding region of SPPL3 have recently been linked to breast cancer as a risk factor (183).

SPPL2c can also affect the glycosylation pattern of glycoproteins, though through a different pathway than SPPL3 as it has been shown that these two proteases do not have substrate overlap (25). Nonetheless, through the cleavage of SNARE molecules SPPL2c disrupts the trafficking of glycosidases and glycosyltransferases (Figure 6). As these proteins need to reach the *trans*-Golgi compartment in order to fully mature and interact with their substrates, numerous glycoproteins with complex N-glycans are hypoglycosylated and do not mature properly upon ectopic expression of SPPL2c (25). This indirect effect of SPPL2c expression on protein glycosylation most likely is also involved in the maturation process of spermatids (25). Under physiological conditions, SPPL2c contributes to the

complex and specific glycosylation pattern of the glycocalyx that surrounds mature sperm and is necessary for species specificity in mating, as it ensures the fusion of the ovum with the sperm (184). A lectin microarray analysis of mature sperm showed a difference in the sperm glycan fingerprint when SPPL2c was knocked-out (25). As SPPL2c is physiologically expressed in humans it would be of interest to check if any variations in the proteases expression and/or function can be connected to infertility. Interestingly, the *SPPL2C* gene is found to be affected in patients suffering from the Koolen-de Vries 17q21 microdeletion syndrome (185, 186). Six genes are in total affected by this deletion that results mainly in mental retardation, however one of the male patients was also found to be infertile (187). The restricted expression of SPPL2c in the organism makes it very unlikely for the protease to contribute to the mental phenotype, however it remains highly probable that it contributes to the fertility phenotype. Further research on the topic and analysis of samples from individuals suffering from infertility could be of great interest.

CONCLUSION

In the past 20 years, a lot of progress has been made in the field of intramembrane proteolysis in general and in context of GxGD aspartyl proteases in particular. With the identification of multiple substrates for these proteases, we now better understand their connection to multiple pathways including the vascular system, cancer progression and many more. We can also appreciate the complexity of their function and the

difficulties in targeting specific protease-substrate combinations. However, in addition to the research performed this far, in order to best understand and target GxGD aspartyl proteases, we would need not only specific inhibitors, like the ones developed by Novartis for SPPL2a (141–143), but also an even more comprehensive understanding of their physiological activity. The lethal phenotype demonstrated by mice lacking some of these proteases in the early developmental stages had posed an obstacle in the past years, nonetheless, the generation of conditional knockout mouse lines will enable leaps of progress in this field.

REFERENCES

1. Rawson RB, Zelenski NG, Nijhawan D, Ye J, Sakai J, Hasan MT, et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. *Mol Cell*. (1997) 1:47–57.
2. Mueller J. *Archiv für Anatomie, Physiologie und wissenschaftliche Medicin*. Berlin: G. Eichler (1836).
3. Naturhistorisch-Medizinischer and Verein. *Verhandlungen*. Heidelberg: Carl Winter's Universitätsbuchhandlung (1877).
4. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. *J Biol Chem*. (2008) 283:29627–31. doi: 10.1074/jbc.R800010200
5. Haapasalo A, Kovacs DM. The many substrates of presenilin/gamma-secretase. *J Alzheimers Dis*. (2011) 25:3–28. doi: 10.3233/JAD-2011-101065
6. Mentrup T, Fluhrer R, Schroder B. Latest emerging functions of SPP/SPPL intramembrane proteases. *Eur J Cell Biol*. (2017) 96:372–82. doi: 10.1016/j.ejcb.2017.03.002
7. Guner G, Lichtenthaler SF. The substrate repertoire of gamma-secretase/presenilin. *Semin Cell Dev Biol*. (2020) 105:27–42. doi: 10.1016/j.semcdb.2020.05.019
8. Hu J, Xue Y, Lee S, Ha Y. The crystal structure of GXGD membrane protease FlaK. *Nature*. (2011) 475:528–31. doi: 10.1038/nature10218
9. Li X, Dang S, Yan C, Gong X, Wang J, Shi Y. Structure of a presenilin family intramembrane aspartate protease. *Nature*. (2013) 493:56–61. doi: 10.1038/nature11801
10. Wolfe MS. Toward the structure of presenilin/gamma-secretase and presenilin homologs. *Biochim Biophys Acta*. (2013) 1828:2886–97. doi: 10.1016/j.bbame.2013.04.015
11. Bai XC, Yan C, Yang G, Lu P, Ma D, Sun L, et al. An atomic structure of human gamma-secretase. *Nature*. (2015) 525:212–7. doi: 10.1038/nature14892
12. Wolfe MS. Intramembrane-cleaving proteases. *J Biol Chem*. (2009) 284:13969–73. doi: 10.1074/jbc.R800039200
13. Manolaidis I, Kulkarni K, Dodd RB, Ogasawara S, Zhang Z, Bineva G, et al. Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1. *Nature*. (2013) 504:301–5. doi: 10.1038/nature12754
14. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. *Nat Cell Biol*. (2000) 2:848–51. doi: 10.1038/35041097
15. Grigorenko AP, Moliaka YK, Korovaitseva GI, Rogaev EI. Novel class of polytopic proteins with domains associated with putative protease activity. *Biochemistry (Mosc)*. (2002) 67:826–35. doi: 10.1023/a:1016365227942
16. Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel family of presenilin homologues. *Hum Mol Genet*. (2002) 11:1037–44. doi: 10.1093/hmg/11.9.1037
17. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. *Science*. (2002) 296:2215–8. doi: 10.1126/science.1070925
18. Voss M, Schroder B, Fluhrer R. Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases. *Biochim Biophys Acta*. (2013) 1828:2828–39. doi: 10.1016/j.bbame.2013.03.033
19. Mentrup T, Cabrera-Cabrera F, Fluhrer R, Schroder B. Physiological functions of SPP/SPPL intramembrane proteases. *Cell Mol Life Sci*. (2020) 77:2959–79. doi: 10.1007/s00018-020-03470-6

AUTHOR CONTRIBUTIONS

AP and RF wrote the manuscript. Both authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) – 263531414/FOR 2290 and 254872893/FL 635/2-2.

20. Lichtenthaler SF, Lemberg MK, Fluhrer R. Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments. *EMBO J*. (2018) 37:e99456. doi: 10.15252/embj.201899456
21. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. *Cell*. (2000) 100:391–8. doi: 10.1016/s0092-8674(00)80675-3
22. Boname JM, Bloor S, Wandel MP, Nathan JA, Antrobus R, Dingwell KS, et al. Cleavage by signal peptide peptidase is required for the degradation of selected tail-anchored proteins. *J Cell Biol*. (2014) 205:847–62. doi: 10.1083/jcb.201312009
23. Hsu FF, Yeh CT, Sun YJ, Chiang MT, Lan WM, Li FA, et al. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. *Oncogene*. (2015) 34:2360–70. doi: 10.1038/ncr.2014.166
24. Niemeyer J, Mentrup T, Heidasch R, Muller SA, Biswas U, Meyer R, et al. The intramembrane protease SPPL2c promotes male germ cell development by cleaving phospholamban. *EMBO Rep*. (2019) 20:e46449. doi: 10.15252/embr.201846449
25. Papadopoulou AA, Muller SA, Mentrup T, Shmueli MD, Niemeyer J, Haug-Kroper M, et al. Signal peptide peptidase-like 2c (SPPL2c) impairs vesicular transport and cleavage of SNARE proteins. *EMBO Rep*. (2019) 20:e46451. doi: 10.15252/embr.201846451
26. Lemberg MK, Freeman M. Cutting proteins within lipid bilayers: rhomboid structure and mechanism. *Mol Cell*. (2007) 28:930–40. doi: 10.1016/j.molcel.2007.12.003
27. Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. *J Neurochem*. (2011) 117:779–96. doi: 10.1111/j.1471-4159.2011.07248.x
28. Voss M, Kunzel U, Higel F, Kuhn PH, Colombo A, Fukumori A, et al. Shedding of glycan-modifying enzymes by signal peptide peptidase-like 3 (SPPL3) regulates cellular N-glycosylation. *EMBO J*. (2014) 33:2890–905. doi: 10.15252/embj.201488375
29. Kuhn PH, Voss M, Haug-Kroper M, Schroder B, Schepers U, Brase S, et al. Secretome analysis identifies novel signal peptide peptidase-like 3 (Sppl3) substrates and reveals a role of Sppl3 in multiple Golgi glycosylation pathways. *Mol Cell Proteomics*. (2015) 14:1584–98. doi: 10.1074/mcp.M115.048298
30. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. (1995) 269:973–7.
31. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome 1. *Science*. (1995) 269:970–3.
32. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature*. (1995) 376:775–8. doi: 10.1038/376775a0
33. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature*. (1995) 375:754–60. doi: 10.1038/375754a0
34. Cruts M, Hendriks L, Van Broeckhoven C. The presenilin genes: a new gene family involved in Alzheimer disease pathology. *Hum Mol Genet*. (1996) 5:1449–55.

35. Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. *J Biol Chem.* (1999) 274:28669–73.
36. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature.* (1999) 398:513–7. doi: 10.1038/19077
37. Fluhrer R, Grammer G, Israel L, Condron MM, Haffner C, Friedmann E, et al. A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b. *Nat Cell Biol.* (2006) 8:894–6. doi: 10.1038/ncb1450
38. Friedmann E, Hauben E, Maylandt K, Schlegler S, Vreugde S, Lichtenthaler SE, et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. *Nat Cell Biol.* (2006) 8:843–8. doi: 10.1038/ncb1440
39. Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Luckerath K, Friedmann E, et al. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. *Cell Death Differ.* (2007) 14:1678–87. doi: 10.1038/sj.cdd.4402175
40. Tomita T, Watabiki T, Takikawa R, Morohashi Y, Takasugi N, Kopan R, et al. The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins. *J Biol Chem.* (2001) 276:33273–81. doi: 10.1074/jbc.M011152200
41. Wang J, Brunkan AL, Hecimovic S, Walker E, Goate A. Conserved PAL sequence in presenilins is essential for gamma-secretase activity, but not required for formation or stabilization of gamma-secretase complexes. *Neurobiol Dis.* (2004) 15:654–66. doi: 10.1016/j.nbd.2003.12.008
42. Wang J, Behr D, Nyborg AC, Shearman MS, Golde TE, Goate A. C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. *J Neurochem.* (2006) 96:218–27. doi: 10.1111/j.1471-4159.2005.03548.x
43. Sato C, Takagi S, Tomita T, Iwatsubo T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. *J Neurosci.* (2008) 28:6264–71. doi: 10.1523/JNEUROSCI.1163-08.2008
44. Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y. Recognition of the amyloid precursor protein by human gamma-secretase. *Science.* (2019) 363:6428. doi: 10.1126/science.aaw0930
45. Friedmann E, Lemberg MK, Weihofen A, Dev KK, Dengler U, Rovelli G, et al. Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. *J Biol Chem.* (2004) 279:50790–8. doi: 10.1074/jbc.M407898200
46. Nyborg AC, Jansen K, Ladd TB, Fauq A, Golde TE. A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin. *J Biol Chem.* (2004) 279:43148–56. doi: 10.1074/jbc.M405879200
47. Nyborg AC, Ladd TB, Jansen K, Kukar T, Golde TE. Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase. *FASEB J.* (2006) 20:1671–9. doi: 10.1096/fj.06-5762com
48. Miyashita H, Maruyama Y, Isshiki H, Osawa S, Ogura T, Mio K, et al. Three-dimensional structure of the signal peptide peptidase. *J Biol Chem.* (2011) 286:26188–97. doi: 10.1074/jbc.M111.260273
49. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. *Nat Cell Biol.* (2003) 5:486–8. doi: 10.1038/ncb960
50. Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100–150-kDa molecular mass complex. *J Biol Chem.* (1998) 273:3205–11.
51. Prokop S, Shirotani K, Edbauer D, Haass C, Steiner H. Requirement of PEN-2 for stabilization of the presenilin N/C-terminal fragment heterodimer within the gamma-secretase complex. *J Biol Chem.* (2004) 279:23255–61. doi: 10.1074/jbc.M401789200
52. Bai XC, Rajendra E, Yang G, Shi Y, Scheres SH. Sampling the conformational space of the catalytic subunit of human gamma-secretase. *Elife.* (2015) 4:e11182. doi: 10.7554/eLife.11182
53. Lee SF, Shah S, Yu C, Wigley WC, Li H, Lim M, et al. A conserved GXXXG motif in APH-1 is critical for assembly and activity of the gamma-secretase complex. *J Biol Chem.* (2004) 279:4144–52. doi: 10.1074/jbc.M309745200
54. Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q, et al. Nicastrin functions as a gamma-secretase-substrate receptor. *Cell.* (2005) 122:435–47. doi: 10.1016/j.cell.2005.05.022
55. Lu P, Bai XC, Ma D, Xie T, Yan C, Sun L, et al. Three-dimensional structure of human gamma-secretase. *Nature.* (2014) 512:166–70. doi: 10.1038/nature13567
56. Kamp F, Winkler E, Trambauer J, Ebke A, Fluhrer R, Steiner H. Intramembrane proteolysis of beta-amyloid precursor protein by gamma-secretase is an unusually slow process. *Biophys J.* (2015) 108:1229–37. doi: 10.1016/j.bpj.2014.12.045
57. Huang Y, Chanou A, Kranz G, Pan M, Kohlbauser V, Ettinger A, et al. Membrane-associated epithelial cell adhesion molecule is slowly cleaved by gamma-secretase prior to efficient proteasomal degradation of its intracellular domain. *J Biol Chem.* (2019) 294:3051–64. doi: 10.1074/jbc.RA118.005874
58. Dickey SW, Baker RP, Cho S, Urban S. Proteolysis inside the membrane is a rate-governed reaction not driven by substrate affinity. *Cell.* (2013) 155:1270–81. doi: 10.1016/j.cell.2013.10.053
59. Yonemura Y, Futai E, Yagishita S, Suo S, Tomita T, Iwatsubo T, et al. Comparison of presenilin 1 and presenilin 2 gamma-secretase activities using a yeast reconstitution system. *J Biol Chem.* (2011) 286:44569–75. doi: 10.1074/jbc.M111.270108
60. Meckler X, Checler F. Presenilin 1 and Presenilin 2 target gamma-secretase complexes to distinct cellular compartments. *J Biol Chem.* (2016) 291:12821–37. doi: 10.1074/jbc.M115.708297
61. Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, et al. Restricted Location of PSEN2/gamma-secretase determines substrate specificity and generates an intracellular abeta pool. *Cell.* (2016) 166:193–208. doi: 10.1016/j.cell.2016.05.020
62. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature.* (1998) 391:387–90. doi: 10.1038/34910
63. Langosch D, Steiner H. Substrate processing in intramembrane proteolysis by gamma-secretase—the role of protein dynamics. *Biol Chem.* (2017) 398:441–53. doi: 10.1515/hsz-2016-0269
64. Wolfe MS. Dysfunctional gamma-secretase in familial Alzheimer's disease. *Neurochem Res.* (2019) 44:5–11. doi: 10.1007/s11064-018-2511-1
65. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *EMBO J.* (2010) 29:3020–32. doi: 10.1038/emboj.2010.167
66. Dulin F, Leveille F, Ortega JB, Mornon JP, Buisson A, Callebaut I, et al. P3 peptide, a truncated form of A beta devoid of synaptotoxic effect, does not assemble into soluble oligomers. *FEBS Lett.* (2008) 582:1865–70. doi: 10.1016/j.febslet.2008.05.002
67. Selkoe DJ. The molecular pathology of Alzheimer's disease. *Neuron.* (1991) 6:487–98.
68. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* (1992) 256:184–5.
69. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol.* (2007) 8:101–12. doi: 10.1038/nrm2101
70. Schettini G, Govoni S, Racchi M, Rodriguez G. Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role—relevance for Alzheimer pathology. *J Neurochem.* (2010) 115:1299–308. doi: 10.1111/j.1471-4159.2010.07044.x
71. Bukhari H, Glotzbach A, Kolbe K, Leonhardt G, Looze C, Muller T. Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease. *Prog Neurobiol.* (2017) 156:189–213. doi: 10.1016/j.pneurobio.2017.05.005
72. Behnke J, Schneppenheim J, Koch-Nolte F, Haag F, Saftig P, Schroder B. Signal-peptide-peptidase-like 2a (SPPL2a) is targeted to lysosomes/late

- endosomes by a tyrosine motif in its C-terminal tail. *FEBS Lett.* (2011) 585:2951–7. doi: 10.1016/j.febslet.2011.08.043
73. Schneppenheim J, Huttli S, Mentrup T, Lullmann-Rauch R, Rothaug M, Engelke M, et al. The intramembrane proteases signal Peptide peptidase-like 2a and 2b have distinct functions *in vivo*. *Mol Cell Biol.* (2014) 34:1398–411. doi: 10.1128/MCB.00038-14
 74. Voss M, Fukumori A, Kuhn PH, Kunzel U, Klier B, Grammer G, et al. Foamy virus envelope protein is a substrate for signal peptide peptidase-like 3 (SPPL3). *J Biol Chem.* (2012) 287:43401–9. doi: 10.1074/jbc.M112.371369
 75. Mentrup T, Theodorou K, Cabrera-Cabrera F, Helbig AO, Happ K, Gijbels M, et al. Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis. *J Exp Med.* (2019) 216:807–30. doi: 10.1084/jem.20171438
 76. Hsu FF, Chou YT, Chiang MT, Li FA, Yeh CT, Lee WH, et al. Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation. *Oncogene.* (2019) 38:1688–701. doi: 10.1038/s41388-018-0539-y
 77. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. *Nature.* (1997) 385:729–33. doi: 10.1038/385729a0
 78. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor- α . *Nature.* (1997) 385:733–6. doi: 10.1038/385733a0
 79. Kontomanolis EN, Kalagasidou S, Pouliliou S, Anthoulaki X, Georgiou N, Papamanolis V, et al. The notch pathway in breast cancer progression. *ScientificWorldJournal.* (2018) 2018:2415489. doi: 10.1155/2018/2415489
 80. Avci D, Malchus NS, Heidach R, Lorenz H, Richter K, Nessling M, et al. The intramembrane protease SPP impacts morphology of the endoplasmic reticulum by triggering degradation of morphogenic proteins. *J Biol Chem.* (2019) 294:2786–800. doi: 10.1074/jbc.RA118.005642
 81. Nakagawa TY, Rudensky AY. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. *Immunol Rev.* (1999) 172:121–9. doi: 10.1111/j.1600-065x.1999.tb01361.x
 82. Martin-Ventura JL, Madrigal-Matute J, Munoz-Garcia B, Blanco-Colio LM, Van Oostrom M, Zalba G, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. *Cardiovasc Res.* (2009) 83:586–94. doi: 10.1093/cvr/cvp141
 83. Sun J, Hartvigsen K, Chou MY, Zhang Y, Sukhova GK, Zhang J, et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. *Circulation.* (2010) 122:808–20. doi: 10.1161/CIRCULATIONAHA.109.891887
 84. Tilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. *Expert Opin Ther Targets.* (2017) 21:671–83. doi: 10.1080/14728222.2017.1336227
 85. Folkman J. Tumor angiogenesis. *Adv Cancer Res.* (1985) 43:175–203. doi: 10.1016/s0065-230x(08)60946-x
 86. Risau W. Mechanisms of angiogenesis. *Nature.* (1997) 386:671–4. doi: 10.1038/386671a0
 87. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. *Cardiovasc Res.* (2001) 49:507–21. doi: 10.1016/s0008-6363(00)00281-9
 88. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. *Cell.* (2011) 146:873–87. doi: 10.1016/j.cell.2011.08.039
 89. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. *Cold Spring Harb Perspect Med.* (2013) 3:a006569. doi: 10.1101/cshperspect.a006569
 90. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. *J Biol Chem.* (2006) 281:3604–13. doi: 10.1074/jbc.M507401200
 91. Gridley T. Notch signaling in the vasculature. *Curr Top Dev Biol.* (2010) 92:277–309. doi: 10.1016/S0070-2153(10)92009-7
 92. Cai J, Chen Z, Ruan Q, Han S, Liu L, Qi X, et al. gamma-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1. *J Biol Chem.* (2011) 286:42514–23. doi: 10.1074/jbc.M111.296590
 93. Tetzlaff F, Fischer A. Control of Blood Vessel Formation by Notch Signaling. *Adv Exp Med Biol.* (2018) 1066:319–38. doi: 10.1007/978-3-319-89512-3_16
 94. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, et al. Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev.* (2000) 14:1343–52. doi: 10.1101/gad.14.11.1343
 95. Gridley T. Notch signaling during vascular development. *Proc Natl Acad Sci USA.* (2001) 98:5377–8. doi: 10.1073/pnas.101138098
 96. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. *Bioessays.* (2004) 26:225–34. doi: 10.1002/bies.20004
 97. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, et al. Dosage-sensitive requirement for mouse Dll4 in artery development. *Genes Dev.* (2004) 18:2474–8. doi: 10.1101/gad.1239004
 98. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc Natl Acad Sci USA.* (2004) 101:15949–54. doi: 10.1073/pnas.0407290101
 99. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. *Genes Dev.* (2004) 18:2469–73. doi: 10.1101/gad.1239204
 100. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. *Cancer Res.* (2006) 66:8501–10. doi: 10.1158/0008-5472.CAN-05-4226
 101. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. *Cell.* (1997) 89:629–39. doi: 10.1016/s0092-8674(00)80244-5
 102. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and Dll1 expression in the paraxial mesoderm. *Nature.* (1997) 387:288–92. doi: 10.1038/387288a0
 103. van Tetering G, Vooijs M. Proteolytic cleavage of Notch: HIT and RUN. *Curr Mol Med.* (2011) 11:255–69. doi: 10.2174/156652411795677792
 104. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. *Proc Natl Acad Sci USA.* (1999) 96:11872–7. doi: 10.1073/pnas.96.21.11872
 105. Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. *Genes Dev.* (1994) 8:707–19. doi: 10.1101/gad.8.6.707
 106. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. *Development.* (1995) 121:1533–45.
 107. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. *J Biol Chem.* (2003) 278:34427–37. doi: 10.1074/jbc.M302659200
 108. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. *Am J Pathol.* (2004) 164:1531–5. doi: 10.1016/S0002-9440(10)63711-X
 109. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. *Front Biosci.* (2006) 11:818–29. doi: 10.2741/1839
 110. Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. *Cancer Cell.* (2014) 25:318–34. doi: 10.1016/j.ccr.2014.02.018
 111. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. *Am J Pathol.* (2010) 176:2019–28. doi: 10.2353/ajpath.2010.090908
 112. Li D, Masiero M, Banham AH, Harris AL. The notch ligand JAGGED1 as a target for anti-tumor therapy. *Front Oncol.* (2014) 4:254. doi: 10.3389/fonc.2014.00254
 113. Han J, Ma I, Hendzel MJ, Allalunis-Turner J. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. *Breast Cancer Res.* (2009) 11:R57. doi: 10.1186/bcr2347
 114. Moeller RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. *Nature.* (2009) 462:182–8. doi: 10.1038/nature08543

115. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. *Clin Cancer Res.* (2010) 16:3141–52. doi: 10.1158/1078-0432.CCR-09-2823
116. Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. *Biochim Biophys Acta.* (2013) 1828:2898–907. doi: 10.1016/j.bbame.2013.06.005
117. Mamaeva V, Niemi R, Beck M, Ozliseli E, Desai D, Landor S, et al. Inhibiting notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying gamma-secretase inhibitors. *Mol Ther.* (2016) 24:926–36. doi: 10.1038/mt.2016.42
118. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. *Oncogene.* (2008) 27:5019–32. doi: 10.1038/ncr.2008.149
119. Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, et al. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. *Oncogene.* (2012) 31:93–103. doi: 10.1038/ncr.2011.212
120. Robert-Moreno A, Guiu J, Ruiz-Herguido C, Lopez ME, Ingles-Esteve J, Riera L, et al. Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1. *EMBO J.* (2008) 27:1886–95. doi: 10.1038/emboj.2008.113
121. Zuniga-Pflucker JC. T-cell development made simple. *Nat Rev Immunol.* (2004) 4:67–72. doi: 10.1038/nri1257
122. Rothenberg EV, Taghon T. Molecular genetics of T cell development. *Annu Rev Immunol.* (2005) 23:601–49. doi: 10.1146/annurev.immunol.23.021704.115737
123. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. *Nature.* (2011) 473:230–3. doi: 10.1038/nature09999
124. Sangwan V, Park M. Receptor tyrosine kinases: role in cancer progression. *Curr Oncol.* (2006) 13:191–3.
125. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. *Science.* (2001) 294:2179–81. doi: 10.1126/science.1065412
126. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. *J Biol Chem.* (2002) 277:6318–23. doi: 10.1074/jbc.M110371200
127. Vidal GA, Naresh A, Marrero L, Jones FE. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. *J Biol Chem.* (2005) 280:19777–83. doi: 10.1074/jbc.M412457200
128. Merilahti JAM, Ojala VK, Knittle AM, Pulliainen AT, Elenius K. Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases. *Mol Biol Cell.* (2017) 28:3123–31. doi: 10.1091/mbc.E17-04-0261
129. Merilahti JAM, Elenius K. Gamma-secretase-dependent signaling of receptor tyrosine kinases. *Oncogene.* (2019) 38:151–63. doi: 10.1038/s41388-018-0465-z
130. Wali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, et al. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. *Breast Cancer Res.* (2014) 16:501. doi: 10.1186/s13058-014-0501-z
131. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. *Oncogene.* (2003) 22:1511–6. doi: 10.1038/sj.onc.1206298
132. Cespedes MV, Larriba MJ, Pavon MA, Alamo P, Casanova I, Parreno M, et al. Site-dependent E-cadherin cleavage and nuclear translocation in a metastatic colorectal cancer model. *Am J Pathol.* (2010) 177:2067–79. doi: 10.2353/ajpath.2010.100079
133. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. *Nat Cell Biol.* (2009) 11:162–71. doi: 10.1038/ncb1824
134. Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. *Oncogene.* (2004) 23:503–13. doi: 10.1038/sj.onc.1207173
135. Schmidt JE, Morgan JI, Rodriguez-Galindo C, Webb DL, Liang H, Tamburro RF. Heme oxygenase-1 messenger RNA expression is induced in peripheral blood mononuclear cells of pediatric cancer patients with systemic inflammatory response syndrome. *Pediatr Crit Care Med.* (2004) 5:554–60. doi: 10.1097/01.PCC.0000144709.87365.F0
136. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. *Science.* (2007) 318:977–80. doi: 10.1126/science.1147379
137. Wei JW, Cai JQ, Fang C, Tan YL, Huang K, Yang C, et al. Signal Peptide Peptidase, Encoded by HM13, Contributes to Tumor Progression by Affecting EGFRvIII Secretion Profiles in Glioblastoma. *CNS Neurosci Ther.* (2017) 23:257–65. doi: 10.1111/cns.12672
138. Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, et al. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. *J Biol Chem.* (2003) 278:16528–33. doi: 10.1074/jbc.M301372200
139. Schneppenheim J, Dressel R, Huttel S, Lullmann-Rauch R, Engelke M, Dittmann K, et al. The intramembrane protease SPPL2a promotes B cell development and controls endosomal traffic by cleavage of the invariant chain. *J Exp Med.* (2013) 210:41–58. doi: 10.1084/jem.20121069
140. Mentrup T, Looock AC, Fluhrer R, Schroder B. Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets? *Biochim Biophys Acta Mol Cell Res.* (2017) 1864:2169–82. doi: 10.1016/j.bbamcr.2017.06.007
141. Zhang X, Gotte M, Ibig-Rehm Y, Schuffenhauer A, Kamke M, Beisner D, et al. Identification of SPPL2a inhibitors by multiparametric analysis of a high-content ultra-high-throughput screen. *SLAS Discov.* (2017) 22:1106–19. doi: 10.1177/2472555217719834
142. Velický J, Bodendorf U, Rigollier P, Eppele R, Beisner DR, Guerini D, et al. Discovery of the first potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects *in vivo*. *J Med Chem.* (2018) 61:865–80. doi: 10.1021/acs.jmedchem.7b01371
143. Velický J, Mathison CJN, Nikulin V, Pflieger D, Eppele R, Azimioara M, et al. Discovery of orally active hydroxyethylamine based SPPL2a inhibitors. *ACS Med Chem Lett.* (2019) 10:887–92. doi: 10.1021/acsmchemlett.9b00044
144. Weihofen A, Lemberg MK, Ploegh HL, Bogoy M, Martoglio B. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. *J Biol Chem.* (2000) 275:30951–6. doi: 10.1074/jbc.M005980200
145. Chen CY, Malchus NS, Hehn B, Stelzer W, Avci D, Langosch D, et al. Signal peptide peptidase functions in ERAD to cleave the unfolded protein response regulator XBP1u. *EMBO J.* (2014) 33:2492–506. doi: 10.15252/embj.201488208
146. Hamblet CE, Makowski SL, Tritapoe JM, Pomerantz JL. NK Cell Maturation and Cytotoxicity Are Controlled by the Intramembrane Aspartyl Protease SPPL3. *J Immunol.* (2016) 196:2614–26. doi: 10.4049/jimmunol.1501970
147. Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. *Front Immunol.* (2019) 10:1205. doi: 10.3389/fimmu.2019.01205
148. Lemberg MK, Bland FA, Weihofen A, Braud VM, Martoglio B. Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes. *J Immunol.* (2001) 167:6441–6. doi: 10.4049/jimmunol.167.11.6441
149. El Hage F, Stroobant V, Vergnon I, Baurain JF, Echchakir H, Lazar V, et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. *Proc Natl Acad Sci USA.* (2008) 105:10119–24. doi: 10.1073/pnas.0802753105
150. Oliveira CC, Querido B, Sluijter M, de Groot AF, van der Zee R, Rabelink MJ, et al. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. *J Immunol.* (2013) 191:4020–8. doi: 10.4049/jimmunol.1301496
151. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature.* (1986) 319:675–8. doi: 10.1038/319675a0
152. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. *Annu Rev Immunol.* (1996) 14:619–48. doi: 10.1146/annurev.immunol.14.1.619
153. Beisner DR, Langerak P, Parker AE, Dahlberg C, Otero FJ, Sutton SE, et al. The intramembrane protease Sppl2a is required for B cell and DC

- development and survival via cleavage of the invariant chain. *J Exp Med.* (2013) 210:23–30. doi: 10.1084/jem.20121072
154. Bergmann H, Yabas M, Short A, Miosge L, Barthel N, Teh CE, et al. B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8⁺ dendritic cells require the intramembrane endopeptidase SPPL2A. *J Exp Med.* (2013) 210:31–40. doi: 10.1084/jem.20121076
 155. Kong XF, Martinez-Barricarte R, Kennedy J, Mele F, Lazarov T, Deenick EK, et al. Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. *Nat Immunol.* (2018) 19:973–85. doi: 10.1038/s41590-018-0178-z
 156. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. *J Biol Chem.* (2001) 276:27203–6. doi: 10.1074/jbc.M104684200
 157. Schneppenheim J, Huttli S, Kruchen A, Fluhrer R, Muller I, Saftig P, et al. Signal-peptide-peptidase-like 2a is required for CD74 intramembrane proteolysis in human B cells. *Biochem Biophys Res Commun.* (2014) 451:48–53. doi: 10.1016/j.bbrc.2014.07.051
 158. Rieux-Laucat F, Magerus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. *J Clin Immunol.* (2018) 38:558–68. doi: 10.1007/s10875-018-0523-x
 159. Luckerath K, Kirkin V, Melzer IM, Thalheimer FB, Siele D, Milani W, et al. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. *Blood.* (2011) 117:519–29. doi: 10.1182/blood-2010-07-292722
 160. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol.* (2003) 4:517–29. doi: 10.1038/nrm1155
 161. Makowski SL, Wang Z, Pomerantz JL. A protease-independent function for SPPL3 in NFAT activation. *Mol Cell Biol.* (2015) 35:451–67. doi: 10.1128/MCB.01124-14
 162. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, et al. Presenilins form ER Ca²⁺ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. *Cell.* (2006) 126:981–93. doi: 10.1016/j.cell.2006.06.059
 163. Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. *J Cell Biol.* (2008) 181:1107–16. doi: 10.1083/jcb.200706171
 164. Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, et al. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. *Sci Signal.* (2010) 3:ra22. doi: 10.1126/scisignal.2000818
 165. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. *Nat Rev Neurosci.* (2002) 3:862–72. doi: 10.1038/nrn960
 166. Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. *Cell Calcium.* (2005) 38:427–37. doi: 10.1016/j.ceca.2005.06.021
 167. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. *Nat Rev Mol Cell Biol.* (2012) 13:448–62. doi: 10.1038/nrm3383
 168. Varki A, Freeze HH. Glycans in acquired human diseases. In: Varki A, Cummings RD, editors. *Essentials of Glycobiology*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). p. 553–610.
 169. Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. *Annu Rev Pathol.* (2015) 10:473–510. doi: 10.1146/annurev-pathol-012414-040438
 170. Cheng WK, Oon CE. How glycosylation aids tumor angiogenesis: an updated review. *Biomed Pharmacother.* (2018) 103:1246–52. doi: 10.1016/j.biopha.2018.04.119
 171. Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. *FEBS J.* (2014) 281:46–62. doi: 10.1111/febs.12590
 172. Beyer TA, Sadler JE, Rearick JJ, Paulson JC, Hill RL. Glycosyltransferases and their use in assessing oligosaccharide structure and structure-function relationships. *Adv Enzymol Relat Areas Mol Biol.* (1981) 52:23–175.
 173. Lammers G, Jamieson JC. Studies on the effect of lysosomotropic agents on the release of Gal beta 1-4GlcNAc alpha-2,6-sialyltransferase from rat liver slices during the acute-phase response. *Biochem J.* (1989) 261:389–93.
 174. Paulson JC, Colley KJ. Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. *J Biol Chem.* (1989) 264:17615–8.
 175. Kitazume S, Oka R, Ogawa K, Futakawa S, Hagiwara Y, Takikawa H, et al. Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion *in vivo*. *Glycobiology.* (2009) 19:479–87. doi: 10.1093/glycob/cwp003
 176. Saito T, Miyoshi E, Sasai K, Nakano N, Eguchi H, Honke K, et al. A secreted type of beta 1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity. *J Biol Chem.* (2002) 277:17002–8. doi: 10.1074/jbc.M200521200
 177. Varki A, Esko JD, Colley KJ. Cellular organization of glycosylation. In: Varki A, Cummings RD, editors. *Essentials of Glycobiology*. Cold Spring Harbor, NY (2009). p. 70–73.
 178. Schachter H. The joys of HexNAc. The synthesis and function of N- and O-glycan branches. *Glycoconj J.* (2000) 17:465–83. doi: 10.1023/a:1011010206774
 179. Miyoshi E, Terao M, Kamada Y. Physiological roles of N-acetylglucosaminyltransferase V (GnT-V) in mice. *BMB Rep.* (2012) 45:554–9. doi: 10.5483/bmbrep.2012.45.1090
 180. Drake RR, Ball LE, Abbott KL. *Advances in Cancer Research*. Vol. 126. Amsterdam: Elsevier (2015).
 181. Liu Y, Liu H, Liu W, Zhang W, An H, Xu J. beta1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. *World J Urol.* (2015) 33:1791–9. doi: 10.1007/s00345-014-1451-x
 182. Nagae M, Mizuka Y, Mihara E, Kitago Y, Hanashima S, Ito Y, et al. Structure and mechanism of cancer-associated N-acetylglucosaminyltransferase-V. *Nat Commun.* (2018) 9:3380. doi: 10.1038/s41467-018-05931-w
 183. Noh JM, Kim J, Cho DY, Choi DH, Park W, Huh SJ. Exome sequencing in a breast cancer family without BRCA mutation. *Radiat Oncol J.* (2015) 33:149–54. doi: 10.3857/roj.2015.33.2.149
 184. Pang PC, Chiu PC, Lee CL, Chang LY, Panico M, Morris HR, et al. Human sperm binding is mediated by the sialyl-Lewis(x) oligosaccharide on the zona pellucida. *Science.* (2011) 333:1761–4. doi: 10.1126/science.1207438
 185. Koolen DA, Vissers LE, Pfundt R, de Leeuw N, Knight SJ, Regan R, et al. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. *Nat Genet.* (2006) 38:999–1001. doi: 10.1038/ng1853
 186. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S, et al. Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. *Nat Genet.* (2006) 38:1032–7. doi: 10.1038/ng1858
 187. Moradaliabegi A, Asgarzade N, Rezaei H. A case of Koolen de vries syndrome or 17q21.31 microdeletion syndrome associated with infertility: a case report. *SM J Case Rep.* (2018) 4:1080.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Papadopoulou and Fluhrer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.